CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.
  
  LEARNING OBJECTIVES

  • Develop an understanding of validated and emerging biomarkers of response, such as RAS, BRAF, HER2, microsatellite instability/mismatch repair status and KRAS G12, found in patients with metastatic colorectal cancer (mCRC), and consider the implications for molecular testing and clinical care.
  • Formulate a long-term plan to guide the selection and sequencing of therapy for patients diagnosed with relapsed/refractory (R/R) mCRC, considering their biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
  • Appreciate published research documenting the efficacy of combined BRAF/EGFR inhibition for patients with R/R mCRC and BRAF V600E mutations, and optimally incorporate this therapeutic strategy into clinical care.
  • Recognize available data with HER2-targeted therapy for patients with HER2-positive mCRC, and consider the current and future roles of FDA-approved and investigational approaches.
  • Appraise published research establishing the effectiveness of rechallenge with EGFR antibody therapy, and determine which patients are likely to benefit from this therapeutic maneuver.
  • Apply available and emerging research to optimize the selection and sequencing of later-line therapeutic options for patients with multiregimen-relapsed mCRC, considering the implications of recently presented Phase III clinical trial findings.
  • Recall ongoing trials evaluating novel agents and strategies for mCRC, and use this information to appropriately refer patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/RRmCRC2023/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/RRmCRC2023/Video.
  
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/RRmCRC2023/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/RRmCRC2023.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Kristen K Ciombor, MD, MSCI
  Associate Professor of Medicine
  Division of Hematology/Oncology
  Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Exelixis Inc, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis, Pfizer Inc, Replimune, Seagen Inc; Consulting Agreements: Merck, Pfizer Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol Myers Squibb, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc.
  
  J Randolph Hecht, MD
  Professor of Clinical Medicine
  Director, UCLA GI Oncology Program
  Carol and Saul Rosenzweig Chair in Cancer Therapies Development
  UCLA David Geffen School of Medicine
  Santa Monica, California
  
  Consulting Agreements: Astellas, Deciphera Pharmaceuticals Inc, Galvanize, IGM Biosciences Inc, Notch Therapeutics, Novartis, Taiho Oncology Inc, Tempus; Contracted Research: A2 Bio, Astellas, Bold Therapeutics, Camurus, Cardiff Oncology, Crinetics Pharmaceuticals, CrystalGenomics, Deciphera Pharmaceuticals Inc, Exelixis Inc, Gilead Sciences Inc, Gritstone bio, Janssen Biotech Inc, Lyell Immunopharma, Mirati Therapeutics Inc, Neogene Therapeutics, NGM Biopharmaceuticals, Tizona Therapeutics Inc; Medical Advisory Boards: Actym Therapeutics, Arum Therapeutics, Cornerstone Pharmaceuticals Inc, Triumvira Immunologics.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Seagen Inc, Taiho Oncology Inc, and Takeda Pharmaceuticals USA Inc.
  
  Release date: October 2023
  Expiration date: October 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.